GlassScriptPhysician profile
Collin Gabriel
NPI 1689295842
$1,714.00
in general payments reported to CMS, 2019-2025
27 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.63 · 2021: $150 · 2022: $237 · 2023: $454 · 2024: $668 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $195.26 | 2021-2022 | |
| Exact Sciences Corporation | $175.05 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $134.31 | 2021-2025 | |
| Dexcom, INC. | $130.11 | 2022-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $106.66 | 2023-2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $60.34 | 2023-2024 | |
| Lilly USA, LLC | $59.29 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $57.35 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $53.73 | 2023-2024 | Gardasil 9, Keytruda, Vaxelis |
| Astellas Pharma US INC | $50.62 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $40.28 | 2022 | |
| Corcept Therapeutics | $35.68 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $29.44 | 2020-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $29.08 | 2023-2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.03 | 2023-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $27.39 | 2022 | |
| Axsome Therapeutics, INC. | $23.89 | 2024 | Auvelity |
| Genzyme Corporation | $21.15 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.10 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $17.92 | 2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.23 | 2022 | |
| Grifols USA, LLC | $17.00 | 2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2023 | |
| Verona Pharma, INC. | $13.68 | 2025 | Ohtuvayre |
| Qiagen, LLC | $11.75 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.